Decisions of the Unified Patent Court recorded under "Life sciences and pharma" in UPC Litigation Watch, the case law database maintained by Dhenne Avocats.
Decisions of the Unified Patent Court in pharmaceuticals, biotechnology and medical devices: validity and sufficiency, SPCs, generic and biosimilar launches, provisional measures and evidence.
121 decisions recorded
By an order of 7 January 2025, made in the parallel infringement actions on EP 2 493 466 (UPC_CFI_145/2024 to UPC_CFI_148/2024, against Accord Healthcare, STADA, Reddy and Zentiva), Judge Zigann, judge-rapporteur at the Munich Local Division, substituted Sanofi Winthrop Industrie for Sanofi-Aventis…
By an order of 30 December 2024 (UPC_CFI_400/2024, ORD_60558/2024), the judge-rapporteur of the Milan Local Division (Judge Zana) dismissed Insulet's application for a costs decision against Eoflow, whose application to intervene in support of A.
By an order of 23 December 2024 (UPC_CFI_380/2024, ORD_59988/2024), the judge-rapporteur of the Milan Central Division (Judge Postiglione) ordered A. Menarini Diagnostics to pay Insulet EUR 1,764 for the costs of opposing its application to intervene, refused on 1 October 2024, in…
In an order of 20 December 2024 (UPC_CoA_402/2024), the Court of Appeal dismissed Alexion’s appeal against the Hamburg Local Division’s refusal to grant provisional measures against Samsung Bioepis’s marketing of Epysqli®, a biosimilar of Soliris® (eculizumab), under EP 3 167 888.
By an order of 20 December 2024 (UPC_CFI_541/2024), made after an oral hearing, the Mannheim Local Division (Judge Tochtermann presiding, Judge Böttcher as judge-rapporteur, Judge Mlakar) granted G.
In an order of 20 December 2024 (UPC_CoA_405/2024), the Court of Appeal dismissed Alexion’s appeal against the Hamburg Local Division’s refusal to grant provisional measures against Amgen’s marketing of BEKEMV®, a biosimilar of Soliris® (eculizumab), under EP 3 167 888.
By order of 22 November 2024 (UPC_CFI_400/2024, App_40442/2024), made after the hearing of 15 October 2024, the Milan Local Division (panel presided over by P. Perrotti) dismissed Insulet Corporation's application for provisional measures against A.
By order of 22 November 2024 (UPC_CFI_380/2024), made after the hearing of 16 October 2024, the Milan Central Division (panel presided over by A. Postiglione) dismissed Insulet Corporation's application for provisional measures against EOFLOW Co., Ltd.
In an order of 9 October 2024 (UPC_CoA_584/2024), the Court of Appeal refused EOFlow’s request to expedite its appeal against the order of 24 September 2024 of the Milan Central Division, which had declined to join Insulet’s application for provisional measures against…
By order of 1 October 2024 (UPC_CFI_400/2024, ORD_51903/2024, App_40442/2024), the Milan Local Division (P. Perrotti, presiding, A.
By order of 1 October 2024 (UPC_CFI_380/2024, ORD_52068/2024), the Milan Central Division (A. Postiglione, presiding and judge-rapporteur, A.-L.
By order of 1 October 2024 (UPC_CFI_400/2024), the Milan Local Division dismissed the application of EOFlow, the manufacturer of the EOPatch insulin patch pump, to intervene in support of its exclusive distributor A.
By an order of 24 September 2024 (UPC_CFI_380/2024), the panel of the Milan Central Division (A. Postiglione, presiding judge and judge-rapporteur, A.-L.
By order of 6 September 2024 (UPC_CFI_165/2024, ACT_18492/2024), the Düsseldorf Local Division (R. Thomas, presiding, B.
By order of 6 September 2024 (UPC_CFI_166/2024, ACT_18551/2024), the Düsseldorf Local Division (R. Thomas, presiding, B.
By order of 5 September 2024 (UPC_CoA_106/2024, APL_12739/2024), the Court of Appeal (K. Grabinski, presiding, P.
By order of 5 September 2024 (UPC_CoA_207/2024, APL_24598/2024), the Court of Appeal dismissed Advanced Bionics' appeal against the order of the President of the Court of First Instance of 15 April 2024, which had refused to replace German with English, the language…
By order of 4 September 2024 (UPC_CFI_400/2024, ORD_45723/2024, App_45575/2024), the Milan Local Division (P. Perrotti, presiding, A.
By order of 30 July 2024 (UPC_CoA_402/2024, APL_40470/2024), the Court of Appeal rejected Alexion Pharmaceuticals' request to expedite its appeal against the Hamburg Local Division's dismissal of its application for provisional measures against Samsung Bioepis NL on EP 3 167 888.